Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
0.960
+0.033 (3.58%)
At close: Mar 11, 2025, 4:00 PM
0.940
-0.020 (-2.08%)
After-hours: Mar 11, 2025, 6:55 PM EST
Fate Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 36.06 | 41.87 | 61.33 | 133.58 | 167.35 | Upgrade
|
| Short-Term Investments | 243.01 | 273.31 | 374.89 | 482.33 | 315.57 | Upgrade
|
| Cash & Short-Term Investments | 279.07 | 315.18 | 436.23 | 615.91 | 482.92 | Upgrade
|
| Cash Growth | -11.46% | -27.75% | -29.17% | 27.54% | 118.09% | Upgrade
|
| Accounts Receivable | 3.54 | 1.83 | 38.48 | 8.68 | 5.52 | Upgrade
|
| Other Receivables | 2.1 | 0.9 | 0.8 | 1.1 | 1.5 | Upgrade
|
| Receivables | 5.64 | 2.73 | 39.28 | 9.78 | 7.02 | Upgrade
|
| Prepaid Expenses | 7.2 | 13.64 | 26.57 | 7.73 | 4.39 | Upgrade
|
| Total Current Assets | 291.91 | 331.54 | 502.07 | 633.41 | 494.32 | Upgrade
|
| Property, Plant & Equipment | 110.89 | 158.51 | 176.09 | 162.25 | 99.39 | Upgrade
|
| Long-Term Investments | 27.66 | 0.98 | 4.94 | 100.66 | - | Upgrade
|
| Long-Term Deferred Charges | - | - | 7.2 | 9.87 | 13.51 | Upgrade
|
| Other Long-Term Assets | 10.24 | 15.19 | 15.26 | 15.26 | 15.24 | Upgrade
|
| Total Assets | 440.69 | 506.22 | 705.56 | 921.46 | 622.46 | Upgrade
|
| Accounts Payable | 9.37 | 4.72 | 8.27 | 8.61 | 6.28 | Upgrade
|
| Accrued Expenses | 21.35 | 27.51 | 53.93 | 42.41 | 15.56 | Upgrade
|
| Current Portion of Leases | 7.42 | 6.18 | 5.63 | 5.58 | 3.36 | Upgrade
|
| Current Unearned Revenue | 0.39 | 0.69 | 42.23 | 21.48 | 21.14 | Upgrade
|
| Other Current Liabilities | - | - | 4 | 3.2 | 39.22 | Upgrade
|
| Total Current Liabilities | 38.52 | 39.09 | 114.05 | 81.28 | 85.56 | Upgrade
|
| Long-Term Leases | 77.85 | 97.36 | 103.71 | 109.24 | 93.94 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 27.12 | 46.02 | Upgrade
|
| Other Long-Term Liabilities | 5.6 | 1.35 | 3.86 | 24.97 | 12.48 | Upgrade
|
| Total Liabilities | 121.97 | 137.8 | 221.62 | 242.62 | 238.01 | Upgrade
|
| Common Stock | 0.11 | 0.1 | 0.1 | 0.1 | 0.09 | Upgrade
|
| Additional Paid-In Capital | 1,716 | 1,580 | 1,536 | 1,449 | 941.22 | Upgrade
|
| Retained Earnings | -1,398 | -1,212 | -1,051 | -769.08 | -556.93 | Upgrade
|
| Comprehensive Income & Other | 0.27 | 0.02 | -1.85 | -0.76 | 0.07 | Upgrade
|
| Total Common Equity | 318.72 | 368.41 | 483.94 | 678.84 | 384.44 | Upgrade
|
| Shareholders' Equity | 318.73 | 368.42 | 483.94 | 678.84 | 384.45 | Upgrade
|
| Total Liabilities & Equity | 440.69 | 506.22 | 705.56 | 921.46 | 622.46 | Upgrade
|
| Total Debt | 85.27 | 103.54 | 109.34 | 114.82 | 97.3 | Upgrade
|
| Net Cash (Debt) | 193.8 | 211.64 | 326.89 | 501.09 | 385.62 | Upgrade
|
| Net Cash Growth | -8.43% | -35.26% | -34.76% | 29.95% | 98.26% | Upgrade
|
| Net Cash Per Share | 1.70 | 2.15 | 3.38 | 5.29 | 4.68 | Upgrade
|
| Filing Date Shares Outstanding | 114.6 | 99.24 | 98.16 | 96.43 | 93.78 | Upgrade
|
| Total Common Shares Outstanding | 113.93 | 98.63 | 97.29 | 95.73 | 87.72 | Upgrade
|
| Working Capital | 253.39 | 292.45 | 388.02 | 552.13 | 408.76 | Upgrade
|
| Book Value Per Share | 2.80 | 3.74 | 4.97 | 7.09 | 4.38 | Upgrade
|
| Tangible Book Value | 318.72 | 368.41 | 483.94 | 678.84 | 384.44 | Upgrade
|
| Tangible Book Value Per Share | 2.80 | 3.74 | 4.97 | 7.09 | 4.38 | Upgrade
|
| Machinery | 38.85 | 83.29 | 81.5 | 53.63 | 22.25 | Upgrade
|
| Construction In Progress | - | - | - | - | 18.19 | Upgrade
|
| Leasehold Improvements | 59.49 | 59.04 | 56.78 | 52.95 | 2.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.